



International Perspectives on Stroke Triage, Diagnosis and Treatment

Episode 4: Treatment with Thrombectomy



Society of Vascular and Interventional Neurology

Overview

- Jointly presented by ASA and SVIN
- No CEs available for webinar
- Certificate of Completion is available





Disclosures

- Dr. Santy Ortega: Consultant: Stryker Neurovascular and Medtronic
- Dr. Tudor Jovin: Member steering committee/DSMB): Cerenovus-modest; Member DSMB: Brainsgate-modest; PI DAWN, AURORA: Stryker Neurovascular; Consultant/Advisory Board: Ownership Interest: Silk Road Medical modest; Consultant/Advisory Board: Ownership Interest: FreeOx Biomedical-modest; Consultant/Advisory Board: Ownership Interest: Route 92-modest; Consultant/Advisory Board: Ownership Interest: Viz.ai-modest; Consultant/Advisory Board: Ownership Interest: Corindus; Consultant/Advisory Board: Anaconda- modest; Consultant: Medtronic-modest
- Dr. Dileep Yavagal: Medtronic, Neuralanalytics, Cerenovus, Rapid Medical: Consultant (Modest);
 TIGER study, SWIFT Prime, RECOVER-Stroke: Steering Committee Member; MR RESCUE: Investigator Steering Committee; ESCAPE: DSMB member; NIH, CTSI, Florida Biomedical State Grant, Anderson Family Gift: Grant support
- **Dr. Gisele Silva**: Brazilian Ministry of Health: Directive and Executive Committee Resilient trial; Boehringer Ingelheim: Consultant, Speaker
- Dr. Waldo Guerrero: none





To Ask a Question







Moderators

Santiago Ortega, MD, MSc, FAHA, FSVIN



Waldo Guerrero, MD





Society of Vascular and Interventional Neurology

Panelists

Tudor Jovin, MD



Dileep R. Yavagal, MD, MBBS, FSVIN, FAAN, FAHA



Gisele Silva, MD, PhD, MPH







APPROACH TO THE LVO PATIENT BEYOND THE GUIDELINES

Tudor G. Jovin, MD

Professor and Chair

Department of Neurology

Cooper Medical School of Rowan University

Director, Cooper Neurological Institute



WHAT DO THE GUIDELINES SAY ???

Powers et al., Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019

3.7. Mechanical Thrombectomy

3.7.1. Concomitant With IV Alteplase	COR	LOE	New, Revised, or Unchanged
Patients eligible for IV alteplase should receive IV alteplase even if mechanical thrombectomy is being considered.	1	А	Recommendation reworded for clarity from 2015 Endovascular. See Table XCV in online Data Supplement 1 for original wording.




			Supplement 1 for original wording.	
3.7.1. Concomitant With IV Alteplase (Continued)	COR	LOE	New, Revised, or Unchanged	
2. In patients under consideration for mechanical thrombectomy, observation after IV alteplase to assess for clinical response should not be performed.	III: Harm	B-R	Recommendation revised from 2015 Endovascular.	
3.7.2. 0 to 6 Hours From Onset	COR	LOE	New, Revised, or Unchanged	
 Patients should receive mechanical thrombectomy with a stent retriever if they meet all the following criteria: (1) prestroke mRS score of 0 to 1; (2) causative occlusion of the internal carotid artery or MCA segment 1 (M1); (3) age ≥18 years; (4) NIHSS score of ≥6; (5) ASPECTS of ≥6; and (6) treatment can be initiated (groin puncture) within 6 hours of symptom onset. 	1	А	Recommendation revised from 2015 Endovascular.	
3.7.2. 0 to 6 Hours From Onset (Continued)	COR	LOE	New, Revised, or Unchanged	
2. Direct aspiration thrombectomy as first-pass mechanical thrombectomy is recommended as noninferior to stent retriever for patients who meet all the following criteria: (1) prestroke mRS score of 0 to 1; (2) causative occlusion of the internal carotid artery or M1; (3) age ≥18 years; (4) NIHSS score of ≥6; (5) ASPECTS ≥6; and (6) treatment initiation (groin puncture) within 6 hours of symptom onset.	1	B-R	Recommendation revised from 2015 Endovascular.	
4. Although its benefits are uncertain, the use of mechanical thrombectomy with stent retrievers may be reasonable for patients with AIS in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have prestroke mRS score >1, ASPECTS <6, or NIHSS score <6, and causative occlusion of the internal carotid artery (ICA) or proximal MCA (M1).	IIb	B-R	Recommendation unchanged from 2015 Endovascular.	
5. Although the benefits are uncertain, the use of mechanical thrombectomy with stent retrievers may be reasonable for carefully selected patients with AIS in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have causative occlusion of the anterior cerebral arteries, vertebral arteries, basilar artery, or posterior cerebral arteries.	IIb	C-LD	Recommendation reworded for clarity from 2015 Endovascular. COR unchanged. LOE amended to conform with ACC/AHA 2015 Recommendation Classification System. See Table XCV in online Data Supplement 1 for original wording.	
3.7.3. 6 to 24 Hours From Onset	COR	LOE	New, Revised, or Unchanged	
In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria, mechanical thrombectomy is recommended.	ı	А	New recommendation.	
In selected patients with AIS within 16 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria, mechanical thrombectomy is reasonable.	lla	B-R	New recommendation.	
3. Although the benefits are uncertain, the use of mechanical thrombectomy with stent retrievers may be reasonable for carefully selected patients with AIS in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have causative occlusion of the MCA segment 2 (M2) or MCA segment 3 (M3) portion of the MCAs.	IIb	B-R	Recommendation reworded for clarity from 2015 Endovascular. COR unchanged. LOE revised. See Table XCV in online Data Supplement 1 for original wording.	






Are We Over-Selecting?







Thrombectomy Eligibility



1 in 4 AISs harbor an IVO


Thrombectomy Eligibility per AHA 2018 guidelines-

- 7 in 100 AIS
- 3 in 10 AIS with vessel occlusion
- 1 in 2 AIS with internal carotid or middle cerebral artery M1 occlusion

AHA Eligibility	0-6 hours	6-24 hours	0-24 hours
All Ischemic Strokes	8.3%	5.7%	7.3%
ICA/ MCA-M1	59%	32%	47%











CURRENT STATE OF KNOWLEDGE (0-6 hours)

Known knowns

- Highly effective in most patients with proximal LVO (t-PA and non t-PA)
- Rate of mRS 0-2 still not good enough
- Benefit is time dependent
- Benefit is present in all subpopulations included in studies (age, gender, NIHSS, occlusion location, baseline infarct size)
- No evidence that proof of mismatch is necessary
- No major safety concerns

Known unknowns

- Harm in subpopulations (eg largest infarcts)
- Benefit in populations not studied (distal occlusions, pre-existing disability, mild stroke severity, largest infarcts, BA occlusion)
- Procedural and peri-procedural aspects (stentrievers vs aspiration, GA vs awake, BP, glucose management, adjunctive antithrombotics, primary stenting)
- Effect of advanced imaging helpful/neutral/harmful
- Need for iv thrombolysis (t-PA/TNK) at thrombectomy center





CURRENT STATE OF KNOWLEDGE (beyond 6 hours)

Known knowns

- Highly effective in patients (proximal LVO and mismatch defined by DAWN & DEFUSE 3 criteria)
- Benefit is less strongly associated with time to treatment
- Benefit is not associated with mode of presentation (wake-up vs witnessed vs unwitnessed)
- No major safety concerns

Known unknowns

- Benefit in populations not meeting DAWN/DEFUSE criteria (distal occlusions, pre-existing disability, mild stroke severity, larger infarcts, less or no mismatch, beyond 24 hours)
- Optimal imaging modality for mismatch (clinical vs perfusion, core by CT only vs CTP vs MRI)
- Harm in subpopulations (eg largest infarcts)
- Procedural and peri-procedural aspects
- Role of iv thrombolysis





Research



Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods

Tudor G Jovin¹, Jeffrey L Saver², Marc Ribo³, Vitor Pereira⁴, Anthony Furlan⁵, Alain Bonafe⁶, Blaise Baxter⁷, Rishi Gupta⁸, Demetrius Lopes⁹, Olav Jansen¹⁰, Wade Smith¹¹, Daryl Gress¹², Steven Hetts¹³, Roger J Lewis¹⁴, Ryan Shields¹⁵, Scott M Berry¹⁶, Todd L Graves¹⁶, Tim Malisch¹⁷, Ansaar Rai¹⁸, Kevin N Sheth¹⁹, David S Liebeskind² and Raul G Nogueira²⁰

International Journal of Stroke
0(0) 1-12
© 2017 World Stroke Organization
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1747493017710341
journals.sagepub.com/home/wso


\$SAGE

DAWN may have profound implications for treatment of stroke due to LVO, because it would validate the physiological (rather than chronological) approach to patient selection for endovascular therapy. It will also allow many more patients with LVO stroke to be treated with mechanical embolectomy, especially in countries outside of the US, Australia, Canada, and Western Europe, where due to inadequate development for stroke pre-hospital systems of care, a large proportion of patients with LVO stroke present to endovascular centers outside 6 h from TLSW.





PRESENCE OF (CLINICAL CORE) MISMATCH ACROSS TIME BASED ON ASPECTS



- in the 6-24 window, 79% of ASPECTS 6-10 meet DAWN criteria
- the prevalence of CCM diminishes with time
- even at 24 hours 25% of patients with NIHSS >9 meet DAWN criteria
- proportion of positive DAWN criteria by ASPECTS category is constant in time



CASE SERIES

Interaction between time, ASPECTS, and clinical mismatch

Shashvat M Desai, ¹ Daniel A Tonetti, ² Bradley J Molyneaux, ³ Kunakorn Atchaneeyasakul, ¹ Marcelo Rocha [©], ³ Tudor G Jovin, ⁴ Ashutosh P Jadhay [©] ³



Bottom line: within 6-24 hrs, given NNT of 2 in DAWN,

it is reasonable to assume robust benefit of thrombectomy for ASPECTS 6-10 group (80% of which meet DAWN criteria) as a whole.

LACK OF CTP/MRI SHOULD NOT BE A DETERRENT FROM THROMBECTOMY BEYOND 6 HOURS.ASPECTS IS GOOD ENOUGH.

6:01 PM · Apr 4, 2020 from Haddonfield, NJ · Twitter for Andro	id
III View Tweet activity	
19 Retweets 49 Likes	





CASE SERIES

Thrombectomy 24 hours after stroke: beyond DAWN



Shashvat M Desai, ¹ Diogo C Haussen, ² Amin Aghaebrahim, ³ Alhamza R Al-Bayati, ² Roberta Santos, ³ Raul G Nogueira, ² Tudor G Jovin, ¹ Ashutosh P Jadhav ¹

Table 3 Outcomes			
	DAWN eligible (>24 hours since TLKW) n=21	DAWN trial intervention arm n=107	P values
Procedural outcomes, n (%)			
Rates of TICI ≥2b	17 (81%)	90 (84%)	0.72
Efficacy outcomes, n (%)			
Early neurological recovery	6 (29%)	51 (48%)	0.10
mRS 0-2 at 90 days	9 (43%)	51 (48%)	0.68
Safety outcomes, n (%)			
Neurologic deterioration	2 (10%)	15 (14%)	0.57
Symptomatic ICH	1 (5%)	6 (6%)	0.87
Mortality	4 (19%)	20 (19%)	0.96





I AM OUTSIDE OF CLASS I RECOMMENDATION HOW SHOULD I APPROACH THE PROBLEM? (NOT TREATING IS ALSO AN ACTIVE DECISION)

- IS IT SAFE?
- WHAT IS MORE LIKELY (BASED ON AVAILABLE DATA) BENEFIT/NEUTRAL/HARM?
- AM I GOING TO DEPRIVE THE PATIENT OF A GOOD OUTCOME OPPORTUNITY IF I DON'T TREAT?
- ARE THE RESOURCES JUSTIFIED (IS THIS COST EFFECTIVE)?
- DISCUSS WITH PATIENT/FAMILY





Geographical Disparities and Barriers to Mechanical Thrombectomy Access: A Global Approach to the MT Gap

Dileep Yavagal, MD

Global Co-Chair MT2020





GLOBAL BURDEN OF STROKE: NOW SUBSTANTIALLY MODIFIABLE IN 2020






Fig. 4 Heat map showing incidence of stroke adjusted to the World Health Organization world population by quartiles (8).

Get involved at worldstrokecampaign.org **World Stroke** Organization Feigin et al 2014 -2015, 2The Cochrane Collaboration 2013, 2 Emberson et al 2014, 4 Goyal et al 2016 @WStrokeCampaign #\

stroke treatments.

· Share this information with family and friends

· Advocate in your community for access to stroke treatment Together we can conquer stroke.

Global stroke statistics

Global stroke statistics


Amanda G. Thrift^{1,2}*, Dominique A. Cadilhac^{1,2,3}, Tharshanah Thayabaranathan¹, George Howard⁴, Virginia J. Howard⁵, Peter M. Rothwell⁶, and Geoffrey A. Donnan^{2,3}







RCT Evidence for Immense Benefit of Mechanical Thrombectomy trials in Low- and Middle-Income Countries (LMIC)



ORIGINAL ARTICLE (FREE PREVIEW)

Thrombectomy for Stroke in the Public Health Care System of Brazil

Sheila O. Martins, M.D., Ph.D., Francisco Mont'Alverne, M.D., Ph.D., Letícia C. Rebello, M.D., Daniel G. Abud, M.D., Ph.D., Gisele S. Silva, M.D., Ph.D., Fabrício O. Lima, M.D., Ph.D., Bruno S.M. Parente, M.D., Guilherme S. Nakiri, M.D., Ph.D., Mário B. Faria, M.D., Michel E. Frudit, M.D., Ph.D., João J.F. de Carvalho, M.D., Eduardo Waihrich, M.D., Ph.D., et al., for the RESILIENT Investigators*








MECHANICAL THROMBECTOMY WHILE HIGHLY

COSTLY IS COST-EFFECTIVE

- Health-economic analysis
- Quantify the impact of developing stroke care in the country
- Estimates the impact of gradually increasing uptake of more effective <u>treatments over 10 years</u>
- Estimated <u>cost savings of \$602 million over 15</u> <u>years</u> (\$255 million direct costs, \$348 million indirect costs)



A national economic and clinical model for ischemic stroke care development in Saudi Arabia: A call for change international journal of Stroke
0(0) 1-8
© 2019 World Stroke Organization

Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/1747493019851284







The Access Gap in MT: 2016

- In 2012, Zaidat et al¹ estimated LVO to be
 - 4% to 14% of the total of 675,000 ischemic strokes in the US
- Thus MT eligible patients is the US may range from
 - 27,000 to 97,000 patients annually
- Other estimates of LVOs are approximately
 - 9% to 27% of the total, yielding estimates of 60,750 to 182,250 total LVO in the US
- Total MTs in USA estimated in 2016 was estimated to be under 20,000, a large gap between the need and MT performed
- Worldwide estimate of 10% LVO yields a staggering 1.7M LVO annually
- Total MTs worldwide in 2016: <100,000







Physical Access to MT in USA: Travel Distance to Thrombectomy

- Access to acute stroke intervention for LVO patients in the US in evolution over last decade¹.
- 2011: <u>56%</u> of the U.S. population had access within <u>60 min by ground</u> to endovascular stroke treatment-capable hospitals²
- Recent modeling data³, with an assumption of <u>addition of 20 optimally</u> <u>located CSCs</u> per state, estimate that
- 63% of the U.S. population would have 60-min ground access and 83% would have 60-min ground/ air access to a CSC (57).

^{3.} Mullen MT, Branas CC, Kasner SE, et al. Optimization modeling to maximize population access to comprehensive stroke centers. Neurology 2015; 84:1196–205.




^{1.} Khandelwal et al. J A C C V O L . 67, N O . 22, 2016 Acute Ischemic Stroke Intervention June 7 2016 : 2631 – 4 42642

^{2.} Adeoye O, Albright KC, Carr BG, et al. Geographic access to acute stroke care in the United States. Stroke 2014;45:3019–24.





Major inequalities in acute stroke treatment between and within 44 European countries



programs for reducing stroke-related morbidity and mortality in Europe.

A need to implement tailored stroke care

Delivery target

- Rate of IV t-PA=18%
- Rate of EVT=5%

Access target

- 3 stroke units / 1.000.000
- 1 comprehensive stroke centre / 1.000.000





Figure 1. Choropleth map showing number of stroke units per million population in 42 European countries (mean 2.9, 95% CI 2.3–3.6).





MT 2020: Current US & World MT Procedure Estimates

MT total numbers tracking by "triangulation" method

- Sales
- Independent research organizations
- Public Hospital and Procedure Statistic Databases

US Device Industry estimates

- 2015: 10,000
- 2016: 20,000
- 2017: 32,000
- 2018: 45,000
- 2019: 48,000
- 2020: Projected 50,000-52,000

Worldwide Device Industry estimates

- 2016: 79,000
 - 22k US, 27k Europe, 30k Asia, Australia
- 2017: 106,000
 - 32k US , 30k Europe, 43k: Asia, Australia
- 2018: 156,000
- 2019: 179,000

2020: Goal 2020,00 Projected: 2030,00-2050,00







SVIN: Mission Thrombectomy 2020 (MT2020)



NEWS

ARCHIVES

CAROTID

CODING

DIALYSIS

EMBOLIZATION EVAR LIMB SALVAGE

NEUROINTERVENTION

SVIN Announces Worldwide Effort to Increase Use of Mechanical Thrombectomy for Stroke

SHARE | E-MAIL | PRINT | BOOKMARK

November 30, 2016-The Society of Vascular and Interventional Neurology (SVIN) recently announced the launch of Mission Thrombectomy 2020, an initiative to enhance global







MT2020: Vision & Goals

To be a <u>global, metric-driven, umbrella campaign</u> to reduce death and disability associated with LVO ischemic stroke by accelerating access to Mechanical Thrombectomy through:

- 1. Integrating the disparate knowledge of barriers to MT access worldwide
- 2. Unify multiple efforts by local and specialty societies to accelerate MT access globally.
- 3. Globally double the access to MT every 2 years for the next decade.
- 4. Aim for a goal of 202,000 MT worldwide in 2020







MT 2020: Outcome Metrics


- 1. Global Total MT = or >202,000 in 2020
- 2. Double access to MT every 2 years







How Do Treatments Diffuse? Everett Rodgers Model



Area Under
Graph Shows
Percentage of
Population
with Access

Time and Increase in Access (percentage of population)

Access is constrained by information, facilities and physicians and financial access. Will there be enough specialists for early majority and late majority stages. How will the association control growth and be relevant?







When does a treatment need Public Health Intervention (PHI)

For a treatment to be considered in need of a public health intervention, some criteria must be met:

- 1) <u>large health burden</u>, <u>getting larger</u>
- 2) <u>burden distributed unfairly</u> (i.e., certain segments of the population have unequal access)
- 3) There is a <u>highly effective and safe treatment</u> for the condition
- 4) The treatment is cost-effective.
- 5) there must be evidence that upstream preventive strategies could substantially increase access to the effective treatment; and
- 6) such strategies are not yet in place







Upstream PHI Strategies to increase treatment access:

Upstream strategies:

Strategies that target


- economic, political, and community factors
- that could substantially increase access to the treatment







High income Country MT Access










Low- and Middle-Income Country Access and MT2020 Goals









Patient Access Pillars

- Information and Diagnostic Access
 - availability of information about LVO and triage,
 - to specialists; general and emergency care physicians; health care professionals (EMT, nurses); hospitals; clinics; insurance firms; policy-makers; and, patients.
- Physical Access
 - ability to access Mechanical Thrombectomy procedure for LVO
 - distance to facilities; availability of specialty/expertise in the local area; availability of equipment/devices; and, driven by increased volume of patients (through protocols).

Financial Access

 insurance (private or public); ability to pay for MT; speed of access to payment; and, payment lag (before/at service/after service).







MT 2020 Overall Approach: Simultaneous MT Access Scoring and Intervention

MT Access Score: 3 Pillars (IPF) with 0-10 score

1. Information and Diagnostic Access

- availability of information about LVO and triage,
 - to specialists; general and emergency care physicians; health care professionals (EMT, nurses); hospitals; clinics; insurance firms; policy-makers; and, patients.

2. Physical Access

- ability to access Mechanical Thrombectomy procedure for LVO
 - distance to facilities; availability of specialty/expertise in the local area; availability of equipment/devices; and, driven by increased volume of patients

3. Financial Access

• insurance (private or public); ability to pay for MT; speed of access to payment; and, payment lag (before/at service/after service).

MT Access Interventions: IPF Interventions

- Accelerate LVO Diagnosis and Treatment Information & Awareness
- 2. Accelerate Physical Infrastructure for MT
- 3. Accelerate Financial Ecosystem for LVO MT treatment









SVIN Committee

- Chair Dileep R. Yavagal, MD
- Vice-Chair Ashutosh Jadhav, MD, PhD
- David Liebeskind, MD, FAHA, FAAN, FSVIN
- Ameer Hassan, DO, FSVIN
- Vallabh Janardhan, MD, FSVIN
- · Violiza Inoa, MD
- Santiago Ortega-Gutierrez, MD, FSVIN, FAHA
- Italo Linfante, MD, FAHA, FSVIN
- Raul Nogueira, MD, FSVIN
- Robin Novakovic, MD, FSVIN
- Osama (Sam) Zaidat, MD, MSc, FSVIN
- Syed Zaidi, MD
- · Ossama Yassin, MD
- Urs Fischer, MD

Global Executive Committee

Core Leadership Committee

Dr Dileep R. YavagalChair,
USA

Dr Violiza InoaCoordinating Chair,
USA

Dr Ashutosh JadhavVice - Chair,
USA

Dr Santiago Ortega- GutierrezVice - Chair,

USA

Dr Fawaz Al-Mufti
Government Relations,
USA

PMO

- Orbees Medical
 Anurag Mairal, PhD
 Shyam Venkatesh, PhD
- Project Management
- Strategy Consultant
- Jennifer Potter-Vig, PhD
- Project Manager, SVIN

Co-Chairs Committee

Dr. Andrew Demchuk,Co-Chair,
North America

Dr. Carlos Molina,Co-Chair,
Europe

Country Liaison

Country

Liaison

Dr. Sheila Martins,Co-Chair,
LATAM

Region

Dr. Thomas Leung,Co-Chair,
APAC

Regional Sub-Committees

Chair, Stroke

Chair, MT

Board Member #1

Board Member #2

Board Member #3

Dr. Ossama Mansour,Co-Chair,
MENA

Dr. Zhongrong Miao, Co-Chair, China **Dr. P.N. Sylaja,** Co-Chair, South Asia **Dr. Mehari Gebreyohanns,**Co-Chair,
Sub Saharan Africa

Advisory Committee

- Society Liaisons
- o ASA/AHA
- o ESO
- MENA-SINO
- o WSO
- o SNIS
- WFITN
- o ANGELS
- RENS

- Ralph Sacco
- Larry Goldstein
- Anne Alexandrov- Stroke Coordinator chair
- Sushant Arror- Stroke Coordinator co-chair
- Endorsing Organizations
- o ANZ AN
- NCSNVX
- 5T-StrokeSISSKNANN
- o SNVI










MT2020+ Regional committees launched September 2020

RC status



	No. of GEC	No. of RC (GEC+ Non-GEC)
Region	members	members
Africa	9	16
Asia	9	16
Caribbean	11	12
China	5	7
Eastern		
Europe	11	14
LATAM	34	86
MENA	24	35
North		
America	26	59
Oceania	9	10
Russia	2	2
South Asia	37	75
South East		
Asia	23	37
Western		
Europe	11	12







MT2020 Activities Update Year to Date 2020

- 1. MT2020 GEC Meeting in person at ISC 2020 in LA in February 2020: 90 attendees, Update from 6 continents
- 2. Expansion of GEC to >200 Members Globally
 - 1. GEC members have formed on in process of forming Regional Committees formed or in process in 82 countries.
- 3. Impact of COVID-19 on Stroke Thrombectomy Survey
- 4. Development of MT2020 Global Stroke Coordinator Committee
- 5. White Paper for Health Policy Makers on "Mechanical Thrombectomy For Acute Stroke: Building Stroke Thrombectomy Systems of Care in Your Region; Why And How? A White Paper", finalized.







Regional Committee ACTION Plan for 2020

- 1. MT2020+ White Paper dissemination to local health policy members in the region.
- 2. Regional Survey and Analysis of MT infrastructure and volumes
- Development and Design of Public Health Interventions (PHI) to increase thrombectomy access
 - 1. Plan for Implementation and Evaluation of PHI in 2021
- 4. Global Thrombectomy Tracking (GTT) Smartphone App Enrollment







MT2020: 2020 #1 Global Intervention—Creating White Papers for Health Policy Makers

Objective

 Develop a White Paper that provides policy-makers with data on LVOs and why a global/national/regional and local strategy to increase Mechanical Thrombectomy is needed. There will be three versions of the report for High-Income, Low-Income and Very Low-Income Countries.



STROKE MECHANICAL THROMBECTOMY

Building thrombectomy systems of care in your region; Why and How?

The Society of Vascular and Interventional Neurology (SVIN









MT2020+:2021 #1. Patient Journey Educational Materials: (HI,LI, VLI Countries)

• Develop Stroke Patient Journey Materials (will aid in policymakers and healthcare worker education).







MT2020+: 2021

#2: Increase Infrastructure and Payment (LI, VLI countries)

A. International Thrombectomy Stroke Certification Programs: SNVI-SVIN Self Attestation TSC Certification

B. Develop Innovative MT Payment Methods for Low-Income Countries and Very Low-Income Countries.







MT2020: 2021

#3

- A. White Paper in Collaboration with SNIS:
 Rural Access to Stroke Thrombectomy in the US
- B. White paper in collaboration with WFITN (World Federation of Interventional and Therapeutic Neuroradiology):


 Global Demand for Mechanical Thrombectomy and Supply








MT 2020 Smartphone App: Real-time Global and Individual Thrombectomy Tracker



 MT2020 App tracks & stores de-identified MTs performed throughout the world by individual neurointerventionalists geotagged to their Thrombectomy Stroke Center



 Users can keep a track of their case log with getting details of the procedures performed in their region and around the globe.







MT 2020 Smartphone App: Download from App store

- Find it on your smartphone in iPhone or Android APP store: Search for "MT2020"
- Compatibility: Requires iOS 8.0 or later. Compatible with iPhone, iPad, and iPod touch.
- Website for app: www.mt2020.org
- Email: support@mt2020.org







MT 2020: Conclusions

- MT 2020 is a global multi-stakeholder public health campaign to accelerate thrombectomy access for LVO stroke patients with the ultimate goal to lower the death and disability from acute ischemic stroke worldwide
- 2. The campaign hopes to see a goal of >2020,00 MT in one year by end of 2020
 - A feasible goal, in light of the near doubling of the number of MT from 2016 to 2018 to 100,000







MT 2020: Conclusions

- 3. 2019 PHI for MT2020:
 - I. White Paper on Building Thrombectomy Capacity: Why & How
 - II. Patient Journey Materials,
 - III. Thrombectomy Center Certification for LI and VLI countries







International Perspectives on Stroke Triage, Diagnosis, and Treatment Mechanical Thrombectomy in Brazil

Gisele Sampaio Silva MD, PhD, MPH





Agenda

- Barriers to mechanical thrombectomy in Brazil: costs, system organization and gaps
- Opportunities to increase access to stroke treatment
- Considerations in accessing mechanical thrombectomy in various countries and regions of the world





Latin America in Numbers



Country	Area km²	Population
Argentina	2 791 810 km²	39 745 613
Bolívia	1 098 581 km²	9 627 269
♦ Brasil	8 515 767 km²	200 104 749
Chile	756 950 km²	16 598 074
Colômbia	1 141 748 km²	44 379 598
Equador	256 370 km²	13 810 000
Guiana	214 970 km²	751 000
Guiana Francesa (França) **	86 504 km²	209 000
Ilhas Malvinas (Reino Unido) *	12 200 km²	3 060
Ilhas Geórgia do Sul e Sandwich do Sul (Reino Unido) *	4 057 km²	100
Paraguai	406 750 km²	6 100 000
Peru	1 285 220 km²	28 674 757
Suriname	163 270 km²	470 000
Uruguai	176 220 km²	3 399 237
Venezuela	916 445 km²	27 934 783





Stroke as a Cause of Death in South America







PROCEEDINGS

Neuroemergencies in South America: How to Fill in the Gaps?

Gisele Sampaio Silva^{1*}, Nelson J. Maldonado², Jorge H. Mejia-Mantilla³, Santiago Ortega-Gutierrez⁴, Jan Claassen⁵, Panayiotis Varelas⁶ and Jose I. Suarez⁷ on behalf of The Galapagos Neurocritical Care Summit Investigators






Fig. 1 South American countries with populations and health systems [1, 9]











Intravenous thrombolysis

Thrombectomy









Research



Georeferencing deaths from stroke in São Paulo: an intra-city stroke belt?

Alexandre O. Kaup¹, Bento F. C. Dos Santos², Elivane S. Victor³, Adriana S. Cypriano⁴, Claudio Luiz Lottenberg², Miguel Cendoroglo Neto², and Gisele S. Silva^{1,5*}




Fig. 1 Spatial visualization of districts with low human development index and high stroke mortality and in São Paulo.







Quem Somos

Depoimentos

Escalas de Avalição do AVC

Estatuto

Eventos

Links Importantes

Missão

Nossos Parceiros

O que é AVC?

Para Pacientes e Familiares

Para Profissionais de Saude

Projetos

Rede de Pesquisa

Rede Nacional de Atendimento ao AVC

Reportagens

Registro SITS

Sinais de Alerta

Portoweb / Portal da Solidariedade / Rede Brasil AVC

Rede Brasil AVC





Notícias

27/10/2009 Dia Mundial do AVC 29 de Outubro: veja o qu acontecerá no

05/10/2009 Dia 29 de Outubro é o Dia Mundial do AVC com o tema AVC: o que eu posso fazer?

23/09/2009 Interrupção do Projeto

Dia Mundial do AVC

O AVC é a principal causa de morte no Brasil. A cada ano, retira do mercado de trabalho milhares de brasileiros e os deixa restritos a uma cama, incapazes de andar, tomar banho ou comer sem ajuda e, portanto, sem dignidade. Mas não precisava ser assim...

O AVC mata anualmente mais de



busca no site



» mapa do site

» contatos

M Fale Conosco





Aprenda a reconhecer os Sinais de Alerta do AVC

SUSPEITA DE AVC? Não espere! Ligue 192 192



PORTARIA Nº. 665, DE 12 DE ABRIL DE 2012

Dispõe sobre os critérios de habilitação dos estabelecimentos hospitalares como Centro de Atendimento de Urgência aos Pacientes com Acidente Vascular Cerebral (AVC), noâmbito do Sistema Único de Saúde (SUS), institui o respectivo incentivo financeiro e aprova a Linha de Cuidados em AVC.



PORTARIA Nº 664, DE 12 DE ABRIL DE 2012

Aprova o Protocolo Clínico e Diretrizes Terapéuticas -Trombólise no Acidente Vascular Cerebral Isquêmico Agudo.







Analysis of the Cost-Effectiveness of Thrombolysis with Alteplase in Stroke

Denizar Vianna Araújo^{1,3}, Vanessa Teich², Roberta Benitez Freitas Passos², Sheila Cristina Ouriques Martins^{3,4}
Universidade do Estado do Rio de Janeiro - UERJ; Medlnsight - Decisions in Health Care², Rio de Janeiro, R.J. Instituto Nacional de Ciência e Tecnologia para Avaliação de Tecnologias em Saúde (IATS) - CNPq³; Hospital de Clínicas de Porto Alegre⁴, Porto Alegre, RS - Brazil

Outcome	Men			Women			
	Treatment with rt-PA	Conservative treatment	Incremental	Treatment with rt-PA	Conservative treatment	Incremental	
QALY	0.47	0.41	0.06	0.47	0.41	0.06	
Cost	R\$ 3,219	R\$ 661	R\$ 2,558	R\$ 2,973	R\$ 661	R\$ 2,312	
RCEI - R\$ / QALY salop			R\$ 40,539			R\$ 36,640	





ARTICLE

The cost of stroke in a public hospital in Brazil: a one-year prospective study

Custo do AVC em um hospital público no Brasil: um estudo prospectivo de um ano

Juliana SAFANELLI¹, Luana Gabriela Dalla Rosa VIEIRA², Tainá de ARAUJO², Lidiana Fachinete Silva MANCHOPE², Maria Helena Ribeiro KUHLHOFF¹, Vivian NAGEL¹, Adriana Bastos CONFORTO^{3,4}, Gisele Sampaio SILVA⁵, Suleimy MAZIN⁷, Pedro Silva Corrêa de MAGALHÃES⁷, Norberto Luiz CABRAL¹




Table 4. IS treatment costs, clinical severity, LOS, and 30-day outcomes.

Title	No reperfusion (n = 134)	IV r-tPA (n = 41)	IV r-tPA + IA thrombectomy (n = 21)	p-value
Age (SD)	62 (13)	66 (14)	66 (12)	0.72
NIHSS (median, IQR)	6 (2-8)	9 (6-12)	19 (13–22)	< 0.0001
Total cost				
US\$ (median, IQR)	2,803 (2,189-3,974)	5,099 (3,304-6,802)	10,997 (10,005–16,955)	< 0.0001
(mean, SD)	2,866 (1,246)	4,978 (2,527)	13,510 (6,711)	< 0.0001
Day cost				
US\$ (median, IQR)	255 (199-361)	364 (236-485)	846 (769-1,304)	< 0.0001
(mean, SD)	261 (113)	356 (181)	1,039(516)	< 0.0001
LOS (mean, SD)	11 (5)	14 (14)	13 (12)	0.11




ARTICLE

The cost of stroke in a public hospital in Brazil: a one-year prospective study

https://doi.org/10.1590/0004-282X20190059

Custo do AVC em um hospital público no Brasil: um estudo prospectivo de um ano

Juliana SAFANELLI¹, Luana Gabriela Dalla Rosa VIEIRA², Tainá de ARAUJO², Lidiana Fachinete Silva MANCHOPE², Maria Helena Ribeiro KUHLHOFF¹, Vivian NAGEL¹, Adriana Bastos CONFORTO^{3,4}, Gisele Sampaio SILVA⁵, Suleimy MAZIN⁷, Pedro Silva Corrêa de MAGALHÃES⁷, Norberto Luiz CABRAL¹






Table 4. Unit costs and average composition of costs per stroke type.

Item cost	Unit costs	IS (n=131)	PIH (n=11)	SAH (n=4)	TIA (n=27)
Hospital-stay					
Nursering	292	268,122	21,920	8,213	7,894
Intensive care days	762	99,876	45,744	22,833	
Medical rounds	47	84,443	29,155	10,161	5,064
Emergency room rounds	55	8,910	1,217	221	2,048
Emergency room rate	30	3,898	327	119	803
Medical procedures*	3,257	219,590	5,196	48,243	1,707
Thrombectomy IA	16,308	130,467			
Physical/Occupational therapy	15	15,914	5,786	1,215	263
Speech therapy	14	8,919	640	218	66



ORIGINAL CONTRIBUTIONS STROKE AWARENESS IN BRAZIL



Alarming Results in a Community-Based Study

Community-Based Study
Octávio Marques Pontes-Neto, MID; Gisele Sampaio Silva, MD, PhD; Markey
Ribeiro Feitosa, MD; Nathalie Lôbo de Figueiredo, MD; José Antonio Fiorot, Jr, MD;
Talitha Ney Rocha; Ayrton Roberto Massaro, MD, PhD; João Pereira Leite, MD, PhD

28 Stroke denominations

22% Did not recognize a symptom























DOI: 10.1590/0004-282X20160174

GUIDELINES

Brazilian guidelines for endovascular treatment of patients with acute ischemic stroke

Diretrizes brasileiras para o tratamento endovascular de pacientes com acidente vascular cerebral isquêmico agudo

Octávio Marques Pontes-Neto*1, Pedro Cougo*1, Sheila Cristina Ouriques Martins2, Daniel G. Abud1, Raul G. Nogueira3, Maramélia Miranda4, Luiz Henrique de Castro-Afonso1, Leticia C. Rebello5, José Guilherme M. Pereira Caldas6, Rodrigo Bazan7, Daniel C Bezerra8, Marco Tulio Rezende9, Gabriel R. de Freitas10,11, Alexandre Longo12, Pedro Magalhães12, João José Freitas de Carvalho13, Francisco José Montalverne13, Fabricio Oliveira Lima13, Gustavo H. V. Andrade14, Ayrton R. Massaro15, Jamary Oliveira-Filho16, Rubens Gagliardi17, Gisele Sampaio Silva18,19





Rationale for possible diffent outcomes of thrombectomy in low resource settings

Stroke second cause of death in Brazil

Thrombectomy cost evaluated as too expensive for the country

Ministry of
Health agreed
to sponsor a
thrombectomy
trial

• Delays in Diagnosis and Transfers

Pre Hospital

• Delays in Triage

Populational

Vulnerable population

Hospital Infrastructure

- Post procedural treatment
- Lack of access to rehalbilitation







RESILIENT

<u>Randomization of Endovascular Treatment with Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke due to Large VEssel Occlusio</u> <u>Trial</u>

for the RESILIENT Trial Investigators Co Chairs: Raul Nogueira and Sheila Martins
















Patient Presentation and Procedural Duration

	Thrombectomy	Clinical Arm
Symptoms onset-to-needle	170 [132-213]	161 [115-219]
Door-to-needle	34 [25-53]	33 [23-50]








The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Thrombectomy for Stroke in the Public Health Care System of Brazil

S.O. Martins, F. Mont'Alverne, L.C. Rebello, D.G. Abud, G.S. Silva, F.O. Lima, B.S.M. Parente, G.S. Nakiri, M.B. Faria, M.E. Frudit, J.J.F. de Carvalho, E. Waihrich, J.A. Fiorot, Jr., F.B. Cardoso, R.C.T. Hidalgo, V.F. Zétola, F.M. Carvalho, A.C. de Souza, F.A. Dias, D. Bandeira, M. Miranda Alves, M.B. Wagner, L.A. Carbonera, J. Oliveira-Filho, D.C. Bezerra, D.S. Liebeskind, J. Broderick, C.A. Molina, J.E. Fogolin Passos, J.L. Saver, O.M. Pontes-Neto, and R.G. Nogueira, for the RESILIENT Investigators*








Field Assessment Stroke Triage for Emergency Destination A Simple and Accurate Prehospital Scale to Detect Large Vessel Occlusion Strokes

Fabricio O. Lima, MD, MPH, PhD; Gisele S. Silva, MD, MPH, PhD; Karen L. Furie, MD, MPH; Michael R. Frankel, MD; Michael H. Lev, MD; Érica C.S. Camargo, MD, PhD, MSc; Diogo C. Haussen, MD; Aneesh B. Singhal, MD; Walter J. Koroshetz, MD; Wade S. Smith, MD; Raul G. Nogueira, MD


Item	FAST-ED Score	NIHSS Score Source	
Facial palsy			
Normal or minor paralysis	0	0-1	
Partial or complete paralysis	1	2-3	
Arm weakness			
No drift	0	0	
Drift or some effort against gravity	1	1-2	
No effort against gravity or no movement	2	3–4	
Speech changes			
Absent	0	0	
Mild to moderate	1	1	
Severe, global aphasia, or mute	2	2-3	
Eye deviation			
Absent	0	0	
Partia l	1	1	
Forced deviation	2	2	
Denial/Neglect			
Absent	0	0	
Extinction to bilateral simultaneous stimulation in only 1 sensory modality	1	1	
Does not recognize own hand or orients only to one side of the body	2	2	



Original Contribution

The FAST-ED App: A Smartphone Platform for the Field Triage of Patients With Stroke

Raul G. Nogueira, MD*; Gisele S. Silva, MD, MPH, PhD*; Fabricio O. Lima, MD, MPH, PhD; Yu-Chih Yeh, PharmD; Carol Fleming, RN; Daniel Branco, MD, PhD; Arthur H. Yancey, MD, MPH; Jonathan J. Ratcliff, MD, MPH; Robert Keith Wages, BS; Earnest Doss; Mehdi Bouslama, MD; Jonathan A. Grossberg, MD; Diogo C. Haussen, MD; Teppei Sakano, BCS; Michael R. Frankel, MD








→ 90% **-**

Regulation of Patients using the FAST ED App





Liste os centros mais próximos





Timeline

Simple Solutions: connecting stroke teams










Patterns of Care and Temporal Trends in Ischemic Stroke Management: A Brazilian Perspective

Monique Bueno Alves, RN, MsC,*† Gisele Sampaio Silva, MD, MPH, PhD,*†
Renata Carolina Acri Miranda, RN,† Rodrigo Meireles Massaud, MD,†
Andreia Maria Heins Vaccari, RN,† Miguel Cendoroglo-Neto, MD, PhD,*† and Solange Diccini, RN, PhD*

Table 3. Adherence to Performance Measures according to the year of discharge


Patterns of care	2009	2010	2011	2012	2013	All	P
IV rtPA (≤3 h) (%)	85.7	100.0	77.8	100.0	91.7	91.3	.397
Early antithrombotics (%)	98.7	100.0	99.1	99.1	100.0	99.4	.673
DVT prophylaxis (%)	100.0	100.0	100.0	100.0	100.0	100.0	ns
Antithrombotics at discharge (%)	90.0	100.0	100.0	95.5	99.1	97.4	<.001
Anticoagulation for AF (%)	66.7	84.6	80.0	73.7	62.5	72.6	.678
Cholesterol reduction* (%)	69.2	78.7	69.0	70.4	88.0	75.6	.003
Smoking cessation (%)	71.4	100.0	70.0	92.3	100.0	84.0	.021
Door-to-CT time (≤45 min) (%)	89.7	70.7	67.3	67.5	66.7	71.1	.210
Mean door-to-CT (min)	33.3 ± 22.9	45.8 ± 37.8	47.8 ± 41.2	41.6 ± 38.2	45.2 ± 23.4	43.6 ± 34.7	.450
Door-to-needle time (≤60 min)	33.3	75.0	61.5	50.0	66.7	58.5	.226
Mean door-to-needle time (min)	82.5 ± 28.4	49.0 ± 20.0	59.3 ± 26.1	64.6 ± 28.59	65.3 ± 30.8	62.6 ± 27.8	.118
Stroke education* (%)	73.1	85.1	78.0	74.8	90.6	80.8	.006
Perfect care (%)	83.0 ± 18.9	90.7 ± 11.7	85.6 ± 17.4	85.8 ± 17.7	92.6 ± 11.4	87.8 ± 15.8	<.001







defuse 3















Panel Discussion

Audience Q & A






To Ask a Question









- Expanded Global Executive
 Committee to over 210 members
- Activated and continue to activate regional committees across the globe across 6 continents
- Researching and developing a mechanical thrombectomy access score
- Global Thrombectomy Tracking (GTT) App

Email: mt2020@svin.org

Website: https://missionthrombectomy2020.org/

MT2020 App: https://mt2020.org/





Upcoming Opportunities

- On-demand viewing
- World Stroke Day (October 29)
 - One CycleNation with ASA
 - Discounted educational opportunities with SVIN
- AHA Scientific Sessions (November 13 17)
- SVIN Annual Conference (November 18 21)
- 2021: Stroke: Vascular and Interventional Neurology journal





Thank You.

The opinions expressed during this webinar are those of the speakers and do not necessarily reflect the opinions, recommendations or guidance of American Stroke Association or Society of Vascular and Interventional Neurology.